



## Application of Docking Methodologies in QSAR-Based Studies

Omar Deeb (Al-Quds University, Palestine), Heidy Martínez-Pachecho (Universidad del Papaloapan, Mexico), Guillermo Ramírez-Galicia (Universidad del Papaloapan, Mexico), and Ramón Garduño-Juárez (Universidad Nacional Autónoma de México, Mexico)

Source Title: Applied Case Studies and Solutions in Molecular Docking-Based Drug Design (/gateway/book/145691)

Copyright: © 2016 | Pages: 27

ISBN13: 9781522503620 | EISBN13: 9781522503637

DOI: 10.4018/978-1-5225-0362-0.ch002

Cite Chapter Favorite

View Full Text HTML (/gateway/chapter/full-text-html/152415) View Full Text PDF (/gateway/chapter/full-text-pdf/152415)

### Abstract

The computational strategies permeate all aspects of drug discovery such as virtual screening techniques. Virtual screening can be classified into ligand based and structure based methods. The ligand based method such as Quantitative Structure Activity Relationship (QSAR) is used when a set of active ligand compounds is recognized and slight or no structural information is available for the receptors. In structure based drug design, the most widespread method is molecular docking. It is widely accepted that drug activity is obtained through the molecular binding of one ligand to receptor. In their binding conformations, the molecules exhibit geometric and chemical complementarity, both of which are essential for successful drug activity. The molecular docking approach can be used to model the interaction between a small drug molecule and a protein, which allow us to characterize the performance of small molecules in the binding site of target proteins as well as to clarify fundamental biochemical processes.

### Full Text Preview

### Introduction

The Molecular modeling expression is used to describe the use of computers to build compounds and carry out a variety of calculations on these compounds in order to predict their chemical characteristics and behavior. The computational strategies also permeate all aspects of drug discovery such as virtual screening techniques in comparison to the process of trial and error that was used in the search for novel drugs.

The most important challenges that medicinal chemists face today is the design of new drugs with improved potency and less side-effects for treating human diseases such as AIDS and others. Medicinal chemists begin the process by taking a lead structure and then finding analogs exhibiting the preferred biological activities. Next, they use their experience and chemical insight to eventually choose a candidate analog for further development. This process was not only difficult but also expensive and time consuming. The conventional methods of drug discovery are now being supplemented by shorter approaches made possible by the accepting of the molecular processes involved in the original disease. In this view, the preliminary point in drug design is the molecular target, which is a receptor or enzyme in the body as an option of the existence of the known lead structure.

The effective design of chemical structures with the desirable therapeutic properties is directed towards Computer Aided-Drug Design (CADD) a well-established area of Computer Aided-Molecular Design (CAMD). The main applications of CAMD are the clarification of the basic requirements for a compound to obtain a determined activity, the simulation of the binding between a ligand and the receptor, the discovery of new active compounds and the prediction of activities for non-synthesized analogues. Two major modeling strategies right now are used in the designing of new drugs. In the first strategy, the design is based on the comparative analysis of the structural features of known active and inactive molecules that are interpreted in terms of their complementarity with a supposed receptor site model. This strategy is called *ligand based design* and one of its approaches is quantitative structure activity relationships (QSAR). This discipline was promoted by Hansch and his group (Fujita, 1990). In the second strategy, the design is based on a known receptor site are directly considered and this strategy is called *structure based design* method. In structure based drug design, the most widespread method is molecular docking (Mahajan A., Gill N.S & Arora R., 2014; Xuan-Yu Meng, Hong-Xing Zhang, Mihaly Mezei & Meng Cui, 2011) The molecular docking approach which will be discussed in details in the coming section can be used to model the interaction between a small drug molecule and a protein, which allow us to characterize the performance of small molecules in the binding site of target proteins as well as to clarify fundamental biochemical processes.

This chapter deals with the two strategies that are used in designing new drugs. At first, focus will be on the ligand based design or QSAR approach. The QSAR section starts with history and the earliest efforts made in this field, types of descriptors and statistical analysis methods. Moreover, validation of QSAR models, the internal as well as the external validations. Second, the focus will be on the structure based design or molecular docking approach. The different types of docking methods will be discussed including the different software used. At the end, applications or case studies done by the authors and others will be discussed also. For example, Exploration of human serum albumin binding sites by docking and molecular dynamics, Docking study related to non-peptide HIV-1 protease inhibitors, Homology modeling, molecular dynamics and docking simulations of rat AZA receptor, Exploring the ligand recognition properties of the human vasopressin V1a receptor using QSAR and molecular modeling studies and others. These studies will introduce the reader to the field of molecular docking and its use in structure based drug design. Finally, more attention must be dedicated to the combination of the two approaches in designing new drugs.

Continue Reading (/gateway/chapter/full-text-html/152415)

### References

- Follow Reference Abbasi M, Ramezani F, Elyasi M, Sadeghi-Aliabadi H, Amanlou M. (2015). A study on quantitative structure-activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold. *DARU Journal of Pharmaceutical Sciences*, 23(1), 29. 10.1186/s40199-015-0111-z25925871
- Follow Reference Akaike H. (1974). A new look at the statistical model identification. *IEEE Transactions on Automatic Control*, 19(6), 716–723. 10.1109/TAC.1974.1100705
- Follow Reference Ambure P. S., Gangwal R. P., Sangamwar A. T. (2012). 3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38 $\alpha$  mitogen-activated protein kinase inhibitors. *Molecular Diversity*, 16(2), 377–388. 10.1007/s11030-011-9353-z2228035
- Follow Reference Anderson M. J., Legendre P. (1999). An empirical comparison of permutation methods for test of partial regression coefficients in a linear model. *Journal of Statistical Computation and Simulation*, 62(3), 271–303. 10.1080/00949659908811936
- Follow Reference Borrelli K. W., Vitalis A., Alcantara R., Guallar V. (2005). PELE: Protein energy landscape exploration. A novel Monte Carlo based technique. *Journal of Chemical Theory and Computation*, 1(6), 1304–1311. 10.1021/ct050181i26631674
- Follow Reference Brooijmans N., Kuntz I. D. (2003). Molecular recognition and docking algorithms. *Annual Review of Biophysics and Biomolecular Structure*, 32(1), 335–373. 10.1146/annurev.biophys.32.110601.14253212574069
- Follow Reference Buolamwini J. K., Assefa H. (2002). CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: Exploration of a binding mode at the active site. *Journal of Medicinal Chemistry*, 45(4), 841–852. 10.1021/jm010399h11831895
- Follow Reference Chen Y. C. (2015). Beware of docking! *Trends in Pharmacological Sciences*, 36(2), 78–95. 10.1016/j.tips.2014.12.00125543280
- Follow Reference Cherkasov A., Ban F., Li Y., Fallahi M., Hammond G. L. (2006). Progressive docking: A hybrid QSAR/docking approach for accelerating in silico high throughput screening. *Journal of Medicinal Chemistry*, 49(25), 7466–7478. 10.1021/jm060961+17149875
- Follow Reference Contreras-Romo M. C., Martínez-Archundia M., Deeb O., Šlusarz M. J., Ramírez-Salinas G., Garduño-Juárez R., Correa-Basurto J. (2014). Exploring the ligand recognition properties of the human vasopressin v1a receptor using QSAR and molecular modeling studies. *Chemical Biology & Drug Design*, 83(2), 207–223. 10.1111/cbdd.1222924010681
- Follow Reference Coupez B., Lewis R. A. (2006). Docking and scoring—theoretically easy, practically impossible? *Current Medicinal Chemistry*, 13(25), 2995–3003. 10.2174/09298670677852179717073642
- Follow Reference Cramer R. D., Patterson D. E., Bunce J. D. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. *Journal of the American Chemical Society*, 110(18), 5959–5967. 10.1021/ja00226a00522148765
- Follow Reference Da C., Mooberry S. L., Gupta J. T., Kellogg G. E. (2013). How to deal with low-resolution target structures: Using SAR, ensemble docking, hydrophobic analysis, and 3D-QSAR to definitively map the  $\beta$ -tubulin colchicine site. *Journal of Medicinal Chemistry*, 56(18), 7382–7395. 10.1021/jm400954h23961916
- Follow Reference Deeb O., da Cunha E. F., Cormanich R. A., Ramalho T. C., Freitas M. P. (2012). Computer-assisted assessment of potentially useful non-peptide HIV-1 protease inhibitors. *Chemometrics and Intelligent Laboratory Systems*, 116, 123–127. 10.1016/j.chemolab.2012.05.003
- Follow Reference Deeb O., Rosales-Hernández M. C., Gómez-Castro C., Garduño-Juárez R., Correa-Basurto J. (2010). Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. *Biopolymers*, 93(2), 161–170. 10.1002/bip.2131419785033
- Follow Reference Devillers J., Balaban A. T. (1999). *Topological Indices and Related Descriptors in QSAR and QSPR* (p. 811). Amsterdam: Gordon Breach Scientific Publishers.
- Follow Reference Duprat A. F., Huynh T., Dreyfus G. (1998). Toward a principled methodology for neural network design and performance evaluation in QSAR. Application to the prediction of log P. *Journal of Chemical Information and Computer Sciences*, 38(4), 586–594. 10.1021/ci980042v9691473
- Follow Reference Eldridge M. D., Murray C. W., Auton T. R., Paolini G. V., Mee R. P. (1997). Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. *Journal of Computer-Aided Molecular Design*, 11(5), 425–445. 10.1023/A:10079961245459385547
- Follow Reference Erickson J. A., Jalaie M., Robertson D. H., Lewis R. A., Vieth M. (2004). Lessons in molecular recognition: The effects of ligand and protein flexibility on molecular docking accuracy. *Journal of Medicinal Chemistry*, 47(1), 45–55. 10.1021/jm030209y14695819
- Follow Reference Ewing T. J. A., Kuntz I. D. (1997). Critical evaluation of search algorithms for automated molecular docking and database screening. *Journal of Computational Chemistry*, 18(9), 1175–1189. 10.1002/(SICI)1096-987X(199707)18:9<1175::AID-JCC6-3.0.CO;2-O
- Follow Reference Fatemi M. H., Heidari A., Gharagani S. (2015). QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors. *Journal of Theoretical Biology*, 369, 13–22. 10.1016/j.jtbi.2015.01.00825600056